Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: Role of adenosine A1/A3 and bradykinin B2 receptor activation

Circulation Research

Volumn 81, Issue 3, 1997, Pages 415-422

  Giannella, Eliana ^a   Mochmann, Hans Christian ^a   Levi, Roberto ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adenosine; Bradykinin; Hypoxic coronary vasodilation; Ischemic preconditioning; Nitric oxide

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; ENDOTHELIUM CELL; ENZYME INHIBITION; GUINEA PIG; HEART MUSCLE ISCHEMIA; HYPOXIA; INSTRUMENTAL CONDITIONING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; REPERFUSION INJURY; VASODILATATION;

EID: 0030792075     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.81.3.415     Document Type: Article

References (65)

1. Feigl EO. Coronary physiology. Physiol Rev. 1983;63:1-205.
2. Park KH, Rubin LE, Gross SS, Levi R. Nitric oxide is a mediator of hvpoxic coronary vasodilatation: relation to adenosine and cyclooxygenase-derived metabolites. Circ Res. 1992;71:992-1001.
3. Bolli R, Triana JF, Jeroudi MO. Prolonged impairment of coronary vasodilation after reversible ischemia: evidence for microvascular 'stunning.' Circ Res. 1990;67:332-343.
4. Sohey CG, Woodman OL. Myocardial ischaemia: what happens to the coronary arteries? Trends Pharmacol Sci. 1993;14:448-453. Erratum: Trends Pharmacol Sci. 1994;15:11.
5. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med. 1994;331: 222-227.
6. 1-agonist in the dog. Br J Pharmacol. 1994;111:1233-1239.
7. Van Benthuysen KM, McMurtry IF, Horwitz LD. Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro. J Clin Invest. 1987;79:265-274.
8. Mehta JL, Nichols WW, Donnelly WH, Lawson DL, Saldeen TGP. Impaired canine coronary vasodilator response to acetylcholine and bradykinin after occlusion-reperfusion. Circ Res. 1989;64:43-54.
9. Pearson PJ, Schaff HV, Vanhoutte PM. Acute impairment of endothelium-dependent relaxations to aggregating platelets following reperfusion injury in canine coronary arteries. Circ Res. 1990;67: 385-393.
10. Evora PRB, Pearson PJ, Schaff HV. Impaired endothelium-dependent relaxation after coronary reperfusion injure: evidence for G-protein dysfunction. Ann Thorac Surg. 1994;57:1550-1556.
11. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136.
12. Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am J Physiol. 1987;253:H1470-H1476.
13. DeFily DV, Chilian WM. Preconditioning protects coronary arteriolar endothelium from ischemia-reperfusion injury. Am J Physiol. 1993;265:H700-H706.
14. Bauer B, Simkhovich BZ, Kloner RA, Przyklenk K. Does preconditioning protect the coronary vasculature from subsequent ischemia/reperfusion injury? Circulation. 1993;88:659-672.
15. Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and repsrfusion. Circulation. 1994;89:1254-1261.
16. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invent. 1975;56:978-985.
17. Bolli R, Zhu WX, Thornby JI, O'Neill PG, Roberts R. Time course and determinants of recovery of function after reversible ischemia in conscious dogs. Am J Physiol. 1998;254;H102-H114.
18. 1 adenosine receptors in rabbit heart. Circulation. 1991;84:350-356.
19. 3 receptors may mediate the protection afforded hy preconditioning in the isolated rabbit heart. Cardiovasc Res. 1994;28:1057-1061. Abstract.
20. ATP channels. Circulation. 1994;89:1229-1236.
21. Downey JM, Cohen MV, Ytrehus K, Liu Y. Cellular mechanisms in ischemic preconditioning: the role of adenosine and protein kinase C. Ann N Y Acad Sci. 1994;723:82-98.
22. 3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci. 1994;15:298-306.
23. 3 receptor involvement. Cardiovasc Res. 1994;28:1049-1056.
24. Vegh A, Szekeres L, Parratt J. Preconditioning of the ischaemic myocardium: involvement of the L-argimne nitric oxide pathway. Br J Pharmacol. 1992;107:648-652.
25. 2 receptors. Br J Pharmacol. 1994;113:1167-1172.
26. Parratt JR. Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci. 1994;15:19-25.
27. Wall TM, Sheehy R, Hartman JC, Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 1994;270:681-689.
28. Thornton JD, Thornton CS, Downey JM. Effect of adenosine receptor blockade: preventing protective preconditioning depends on time of initiation. Am J Physiol. 1993;265:H504-H508.
29. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995;77:611-621.
30. Reimer KA, Murry CE, Yamasawa I, Hill ML, Jennings RB. Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis. Am J Physiol. 1986;251:H1306-H1315.
31. Kitakaze M, Hori M, Takashima S, Sate H, Inoue M, Kamada T. Ischemic preconditioning increases adenosine release and 5′-nudeotidase activity during myocardial ischemia and reperfusion in dogs: implications for myocardial salvage. Circulation. 1993;87: 208-215.
32. Van Wylen DGL. Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia. Circulation. 1994;89:2283-2289.
33. Mizumura T, Nithipatikom K, Gross GJ, Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Circulation. 1995;92:1236-1245.
34. 1-selective adenosine agonists. J Med Chem. 1985;28:1383-1384.
35. 3-selective adenosine agonists. J Med Chem. 1994;37:636-646.
36. 1 subtype-selective adenosine receptor antagonist in the guinea pig isolated heart. J Pharmacol Exp Ther. 1992;260:1292-1299.
37. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, Konig W, Knolle J, Schölkens BA. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102:769-773.
38. Sakuma I, Stuehr DJ, Gross SS, Nathan C, Levi R. Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988;85:8664-8667.
39. Bush PA, Gonzalez NE, Griscavage JM, Ignarro LJ. Nitric oxide synthase from cerebellum catalyzes the formation of equimolar quantities of nitric oxide and citrulline from L-arginine. Biochem Biophys Res Commun. 1992;185:960-966.
40. Kostic MM, Schrader J. Role of nitric oxide in reactive hyperemia of the guinea pig heart. Circ Res. 1992;70:208-212.
41. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO III. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. 1995;92:320-326.
42. Weselcouch EO, Baird AJ, Sleph P, Grover GJ. Inhibition of nitric oxide synthesis does not affect: ischemic preconditioning in isolated perfused rat hearts. Am J Physiol. 1995;268:H242-H249.
43. Lu HR, Remeysen P, De Clerck F. Does the antiarrhythmic effect of ischemic preconditioning in rats involve the L-arginine nitric oxide pathway? J Cardiovasc Pharmacol. 1995;25:524-530.
44. Patel VC, Woolfson RG, Singh KJ, Neild GH, Yellon DM. Ischaemic preconditioning is not prevented by inhibition of endothelium-derived nitric oxide. J Mol Cell Cardiol. 1992;24:S152. Abstract.
45. Li Y, Kloner RA. Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids. Cardiovasc Res. 1992;26: 226-231.
46. Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products. Cardiovasc Res. 1990;24;1020-1023.
47. Busse R, Hecker M, Fleming I. Control of nitric oxide and prostacyclin synthesis in endothelial cells. Arzneimittelforschung. 1994;44: 392-396.
48. Dixon BS, Sharma RV, Dickerson T, Fortune J. Bradykinin and angiotensm II: activation of protein kinase C in arterial smooth muscle. Am J Physiol. 1994;266:C1406-C1420.
49. Tippmer S, Quitterer U, Kolm V, Faussner A, Roscher A, Mosthaf L, Muller-Esterl W, Baring H. Bradykinin induces translocation of the protein kinase C isoforms alpha, epsilon, and zeta. Eur J Biochem. 1994;225:297-304.
50. Armstrong S, Downey JM, Ganote CE. Preconditioning of isolated rabbit cardiomyocytes: induction by metabolic stress and blockade by the adenosine antagonist SPT and calphostin C, a protein kinase C inhibitor. Cardiovasc Res. 1994;28:72-77.
51. Liu Y, Ytrehus K, Downey JM. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol. 1994;26:661-668.
52. + channel?: studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res. 1995;77: 1030-1035.
53. Gross GJ, Yao Z, Pieper GM, Auchampach JA. The ATP-regulated potassium channel in ischemia-reperfusion injury. Ann N Y Acad Sci. 1994;723:71-81.
54. 1-receptors. Circulation. 1992;86:1310-1316.
55. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 1992;70:223-233.
56. Przyklenk K, Sussman MA, Simkhovich BZ, Kloner RA, Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation. 1995;92:1546-1557.
57. Vogt A, Barancik M, Weihrauch D, Anas M, Podzuweit T, Schaper W. Protein kinase C inhibitors reduce infarct size in pig hearts in vivo. Circulation. 1994;90(suppl I):I-647. Abstract.
58. 1-adrenergic signal transduction pathway or protein kinase C in the isolated rat heart. Cardiovasc Drugs Ther. 1996;10:125-136.
59. Vahlhaus C, Schulz R, Post H, Onallah R, Heuseh G. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res. 1996;79:407-414.
60. Brooks G, Hearse DJ. Role of protein kinase C in ischemic preconditioning: player or spectator. Circ Res. 1996;79:627-630.
61. Tsao PS, Lefer AM. Time course and mechanism of endothelial dysfunction in isolated ischemic- and hypoxic-perfused rat hearts. Am J Physiol. 1990;259:H1660-H1666.
62. Matheis G, Sherman MP, Buckberg CD, Haybron DM, Young HH, Ignarro LJ. Role of L-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol. 1992;262:H616-H620.
63. Zweier JL, Wang P, Kuppusamy P. Direct measurement of nitric oxide generation in the ischemic heart using electron paramagnetic resonance spectroscopy. J Biol Chem. 1995;270:304-307.
64. Pabla R, Curtis MJ. Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Circ Res. 1995;77:984-992.
65. ATP channels. Am J Physiol. 1997;272:H334-H342.